"The US Food and Drug Administration (FDA) today approved asfotase alfa (Strensiq, Alexion Pharmaceuticals) as the first-ever therapy for patients who develop hypophosphatasia, a rare metabolic bone disorder, in childhood.
Adverse event information is derived from controlled clinical trials and worldwide marketing experience. In the description below, rates of the more common events represent US/Canadian clinical study results. Less frequent events are also derived from publications and marketing experience in over 8 million patients; there are insufficient data to support an accurate estimate of their incidence rates. These studies were conducted using a variety of premedicants, varying lengths of surgical/diagnostic procedures, and various other anesthetic/sedative agents. Most adverse events were mild and transient.
Anesthesia And MAC Sedation In Adults
The following estimates of adverse events for DIPRIVAN Injectable Emulsion include data from clinical trials in general anesthesia/MAC sedation (N=2889 adult patients). The adverse events listed below as probably causally related are those events in which the actual incidence rate in patients treated with DIPRIVAN Injectable Emulsion was greater than the comparator incidence rate in these trials. Therefore, incidence rates for anesthesia and MAC sedation in adults generally represent estimates of the percentage of clinical trial patients which appeared to have probable causal relationship.
The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established with DIPRIVAN Injectable Emulsion during anesthesia (see below). During MAC sedation clinical trials, significant respiratory events included cough, upper airway obstruction, apnea, hypoventilation, and dyspnea.
Anesthesia In Pediatric Patients
Generally the adverse experience profile from reports of 506 DIPRIVAN Injectable Emulsion pediatric patients from 6 days through 16 years of age in the US/Canadian anesthesia clinical trials is similar to the profile established with DIPRIVAN Injectable Emulsion during anesthesia in adults (see Pediatric percentages [Peds %] below). Although not reported as an adverse event in clinical trials, apnea is frequently observed in pediatric patients.
ICU Sedation In Adults
The following estimates of adverse events include data from clinical trials in ICU sedation (N=159 adult patients). Probably related incidence rates for ICU sedation were determined by individual case report form review. Probable causality was based upon an apparent dose response relationship and/or positive responses to rechallenge. In many instances the presence of concomitant disease and concomitant therapy made the causal relationship unknown. Therefore, incidence rates for ICU sedation generally represent estimates of the percentage of clinical trial patients which appeared to have a probable causal relationship.
Incidence greater than 1% - Probably Causally Related
|Anesthesia/MAC Sedation||ICU Sedation|
|Arrhythmia [Peds: 1.2%]|
|Tachycardia Nodal [Peds: 1.6%]|
|Hypotension* [Peds: 17%] (see also CLINICAL PHARMACOLOGY)||Decreased Cardiac Output|
|Hypertension [Peds: 8%]||Hypotension 26%|
|Central Nervous System:||Movement* [Peds: 17%]|
|Injection Site:||Burning/Stinging or Pain, 17.6% [Peds: 10%]|
|Respiratory:||Apnea (see also CLINICAL PHARMACOLOGY)||Respiratory Acidosis During Weaning*|
|Skin and Appendages:||Rash [Peds: 5%] Pruritus [Peds: 2%]|
|Events without an * or % had an incidence of 1% to 3%
*Incidence of events 3% to 10%
Incidence less than 1% - Probably Causally Related
|Anesthesia/MAC Sedation||ICU Sedation|
|Body as a Whole:||Anaphylaxis/Anaphylactoid Reaction Perinatal Disorder
[Premature Ventricular Contractions]
|Cardiovascular:||Premature Atrial Contractions Syncope|
|Central Nervous System:||Hypertonia/Dystonia, Paresthesia||Agitation|
|Decreased Lung Function|
|Skin and Appendages:||Flushing, Pruritus|
|Urogenital:||Cloudy Urine||Green Urine|
Incidence less than 1% - Causal Relationship Unknown
|Anesthesia/MAC Sedation||ICU Sedation|
|Body as a Whole:||Asthenia, Awareness, Chest Pain, Extremities Pain, Fever, Increased Drug Effect, Neck Rigidity/Stiffness, Trunk Pain||Fever, Sepsis, Trunk Pain, Whole Body Weakness|
|Cardiovascular:||Arrhythmia, Atrial Fibrillation, Atrioventricular Heart Block, Bigeminy, Bleeding, Bundle Branch Block, Cardiac Arrest, ECG Abnormal, Edema, Extrasystole, Heart Block, Hypertension, Myocardial Infarction, Myocardial Ischemia, Premature Ventricular Contractions, ST Segment Depression, Supraventricular Tachycardia, Tachycardia, Ventricular Fibrillation||Arrhythmia, Atrial Fibrillation, Bigeminy, Cardiac Arrest, Extrasystole, Right Heart Failure, Ventricular Tachycardia|
|Central Nervous System:||Abnormal Dreams, Agitation, Amorous Behavior, Anxiety, Bucking/Jerking/Thrashing, Chills/Shivering/Clonic/Myoclonic Movement, Combativeness, Confusion, Delirium, Depression, Dizziness, Emotional Lability, Euphoria, Fatigue, Hallucinations, Headache, Hypotonia, Hysteria, Insomnia, Moaning, Neuropathy, Opisthotonos, Rigidity, Seizures, Somnolence, Tremor, Twitching||Chills/Shivering, Intracranial Hypertension, Seizures, Somnolence, Thinking Abnormal|
|Digestive:||Cramping, Diarrhea, Dry Mouth, Enlarged Parotid, Nausea, Swallowing, Vomiting||Ileus, Liver Function Abnormal|
|Hematologic/ Lymphatic:||Coagulation Disorder, Leukocytosis|
|Injection Site:||Hives/Itching, Phlebitis, Redness/Discoloration|
|Metabolic/ Nutritional:||Hyperkalemia, Hyperlipemia||BUN Increased, Creatinine Increased, Dehydration, Hyperglycemia, Metabolic Acidosis, Osmolality Increased|
|Respiratory:||Bronchospasm, Burning in Throat, Cough, Dyspnea, Hiccough, Hyperventilation, Hypoventilation, Hypoxia, Laryngospasm, Pharyngitis, Sneezing, Tachypnea, Upper Airway Obstruction||Hypoxia|
|Skin and Appendages:||Conjunctival Hyperemia, Diaphoresis,||Rash|
|Special Senses:||Diplopia, Ear Pain, Eye Pain,|
|Nystagmus, Taste Perversion,|
|Urogenital:||Oliguria, Urine Retention||Kidney Failure|
Drug Abuse And Dependence
There are reports of the abuse of propofol for recreational and other improper purposes, which have resulted in fatalities and other injuries. Instances of self-administration of DIPRIVAN Injectable Emulsion by health care professionals have also been reported, which have resulted in fatalities and other injuries. Inventories of DIPRIVAN Injectable Emulsion should be stored and managed to prevent the risk of diversion, including restriction of access and accounting procedures as appropriate to the clinical setting.
Read the Diprivan (propofol) Side Effects Center for a complete guide to possible side effects
The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (e.g., morphine, meperidine, and fentanyl, etc.) and combinations of opioids and sedatives (e.g., benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). These agents may increase the anesthetic or sedative effects of DIPRIVAN Injectable Emulsion and may also result in more pronounced decreases in systolic, diastolic, and mean arterial pressures and cardiac output.
During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (e.g., nitrous oxide or opioids). The concurrent administration of potent inhalational agents (e.g., isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. These inhalational agents can also be expected to increase the anesthetic or sedative and cardiorespiratory effects of DIPRIVAN Injectable Emulsion.
DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity or duration of action of the commonly used neuromuscular blocking agents (e.g., succinylcholine and nondepolarizing muscle relaxants).
No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, analgesic agents, and local anesthetic agents) have been observed in adults. In pediatric patients, administration of fentanyl concomitantly with DIPRIVAN Injectable Emulsion may result in serious bradycardia.
Read the Diprivan Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 6/23/2014
Additional Diprivan Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.